Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2NCUpBg